DarshanTalks Podcast

Send us Fan Mail In December 2023, two US senators raised concerns, urging the government to scrutinize the FDA's oversight of medical device recalls, notably amidst the ongoing Phillips Respironics recall. Join us today as we delve into the world of medical device recalls. Facing a recall is every manufacturer's nightmare, but handling it right is paramount. It safeguards patients, pres...

Send us Fan Mail In a congruency review, the primary objective is to ensure alignment across various elements in clinical research. The initial crucial step involves accurately analyzing Medicare coverage, determining designations based on National and Local Coverage Determinations. This forms the foundation for what is billed to the study sponsor and insurance. Any discrepancies at this stage can...

Send us Fan Mail We delve into the growing allure of clinical research sites and organizations for private equity firms. Backed by BPOC, these investments signify more than just single business deals; they are a testament to the increasing interest in fueling healthcare innovation and services. As this trend gains momentum, thorough due diligence becomes crucial in navigating the complexities of t...

Send us Fan Mail In this episode, the focus is on navigating the complex landscape of off-label information sharing, exploring legal aspects in the context of the life sciences industry. Sponsored by the Kulkarni Law Firm, the episode highlights key points: 1. Scientific discussions: Courts are generally cautious about FDA scrutiny in scientific discussions, such as those in academic conferences o...

Send us Fan Mail Darshan discussed crucial updates to the Department of Justice's (DOJ) corporate enforcement policies, particularly impacting FDA-regulated industries like pharmaceuticals and medical devices. The DOJ's focus on mergers and acquisitions (M&A) emphasizes the importance of compliance professionals throughout the entire process. Key Highlights: 1. Corporate Enforcement...

Send us Fan Mail In this podcast, we discuss the legal and regulatory factors for securing approval for your digital speaker program. Key points include  prioritizing audience privacy,  adhering to FTC disclosure regulations,  explicit audience definition,  distinguishing between educational and promotional content, and  navigating health versus product claims.  Link to the detailed podcast:  http...

Send us Fan Mail FDA Issues Crucial Guidance on Prescription Drug Software!  Darshan Kulkarni delves into the FDA's recent guidance on prescription drug-related software. The discussion revolves around three key considerations: 1. software functions,  2. end-user output, and  3. regulatory guidelines.  Notably, the FDA emphasizes distinguishing between functions relying on direct device data...

Send us Fan Mail Insider Exposes crucial missing step in Clinical Trial Agreements activation - Congruency Review Details Revealed! In the clinical trial agreement activation pathway, the journey involves several critical steps. It begins with the signing of the Confidentiality Disclosure Agreement (CDA), followed by the study team's review of the protocol and feasibility goals. Once the stud...

Send us Fan Mail Accelerate your digital speaker program review with these 5 game-changing strategies:  Policy Creation & Training  Pre-reviews  AI-based Reviews   Modular Reviews Applying Quality Learnings Across the Program Dive deeper into each strategy on our podcast!  Watch the full podcast- https://www.youtube.com/watch?v=Ud8jn4c3cCM  Support the show www.kulkarnilawfirm.com

Send us Fan Mail Darshan Kulkarni emphasizes the importance of selecting the right company for clinical trial recruitment. Key considerations include the company's experience and expertise in a specific disease state or area, its reach (national, international, or local), and the associated costs. He warns against the trend of traditional marketing companies entering the clinical trial recrui...

Send us Fan Mail We discuss five key legal and regulatory considerations for a digital sales force: Starting with updates to the Physician Payment Sunshine Act, emphasizing the need for training, robust internal controls, and monitoring.  It also touches on guidance for interactions with healthcare professionals, emphasizing transparency and ethical practices.  The SIUU guidance is discussed, emph...

Send us Fan Mail We explore the crucial aspects outlined by the FTC regarding comparative claims in drug and device advertising.  the paramount importance of transparency in promotional efforts, the pitfalls associated with broad generalizations, and  the need for readiness in the face of scrutiny from both the FDA and the FTC. Providing a valuable intersection of pharmacy, law, and marketing, our...

Send us Fan Mail In this podcast, we explore a groundbreaking shift where clinical research is emerging as a viable care option, known as Clinical Research as a Care Option (CRACO). While the concept seems promising, particularly for patients with conditions like rare diseases or cancer, it introduces a host of concerns. The alignment of Institutional Review Board (IRB) goals with the essence of a...

Send us Fan Mail In this podcast, we discuss artificial intelligence (AI) and machine learning, exploring their pivotal roles in drug development. AI, a fusion of computer science, statistics, and engineering, employs algorithms to perform tasks like learning, decision-making, and prediction. Within the context of drug development, we unravel three significant applications of AI. First, it aids in...

Send us Fan Mail The National Advertising Division (NAD) recently examined a TV ad by Bravecto, comparing its flea and tick prevention product with NexGard's. The ad suggested Bravecto's greater effectiveness, disputed by NexGard. NAD sided with NexGard, emphasizing the need for clear and conspicuous disclosures in comparative advertising.  In a separate case, Google's ads for YouTu...

Send us Fan Mail In this podcast, five crucial considerations for obtaining approval for a digital speaker program are discussed: 1. Privacy Compliance:    - Consider where audience data will be stored and ensure compliance with privacy laws (TCPA, CCPA, GDPR, etc.).    - Prioritize secure handling of sensitive information and always obtain audience consent. 2. Transparency and Disclosure:    - Ad...

Send us Fan Mail he recently issued FDA guidance mandates manufacturers, packers, and distributors to adhere to new standards, emphasizing mandatory product and facility registrations, creation of safety substantiation information, and implementation of adverse event reporting. Daron breaks down key definitions, clarifies information submission processes, and discusses public accessibility.  Tune...

Send us Fan Mail In this podcast episode, we'll uncover five strategies to expedite the digital promotion review process. Starting with 1. Policy creation and training emphasizes aligning policies across platforms, incorporating key stakeholders' expectations, and ensuring consistency with relevant agreements and guidelines.  2. Pre-review meetings with marketing teams help establish a s...

Send us Fan Mail Darshan Kulkarni delves into the recently released draft guidance by the Center for Devices and Radiological Health (CDRH) outlining best practices for selecting a predicate device when preparing a 510(k) submission. This guidance underscores four key considerations. The draft guidance emphasizes the significance of technological characteristics. If the new device shares the same...

Send us Fan Mail Darshan Kulkarni discusses the FDA's IT strategy for 2024 to 2027. The FDA aims to create a unified FDA ecosystem, promote cross-functional collaboration, and foster a more integrated organizational culture. Key goals include  strengthening IT infrastructure,  modernizing enterprise services, and  optimizing the IT services portfolio for stable, resilient, and adaptive soluti...

Send us Fan Mail In a significant update on September 19th, Samuel Levine, Director of the #FTC's Bureau of Consumer Protection, outlined the agency's key priorities at the National Advertising Division's annual conference. Levine emphasized a three-pillar enforcement agenda.  The first pillar targets practices causing substantial consumer harm,  While the second aims not only to ce...

Send us Fan Mail This week, a data breach was disclosed by 23andMe, affecting 6.9 million users and compromising their genetic data information. The incident raises significant concerns about data privacy and security. It's important to note that while some perceive this as a violation of HIPAA, it typically doesn't apply to direct-to-consumer genetic testing services like 23andMe, as th...

Send us Fan Mail Guest Istvan Fekete discusses what large academic medical institutions are responsible for that sponsors and other commercial entities are generally not. Key considerations include the complexities of handling publication rights, the impact of tax-exempt municipal bonds on project restrictions, ensuring equal patient treatment, the reality of universities generating revenue from i...

Send us Fan Mail In this video,, the focus is on the growing interest in digital engagement programs among FDA-regulated companies, but it also addresses the concerns raised by regulatory agencies such as the FDA, DOJ, FTC, and OIG. The discussion revolves around the risk-based review of outward-facing information shared by medical device companies. The podcast delves into seven hierarchical layer...

Send us Fan Mail Darshan Kulkarni talks about how the generic drug industry is facing several challenges that are impacting profitability, including: 1. Pressure from insurers to lower prices, 2. Rising costs of manufacturing and distribution, 3. Inflation, 4. Supply chain disruptions and 5. Increased competition from other generic companies Pharmacies are fighting back against these challenges by...